Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q09428: Variant p.Phe132Leu

ATP-binding cassette sub-family C member 8
Gene: ABCC8
Feedback?
Variant information Variant position: help 132 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Phenylalanine (F) to Leucine (L) at position 132 (F132L, p.Phe132Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and aromatic (F) to medium size and hydrophobic (L) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In PNDM3; with neurologic features; reduces the sensitivity of the K(ATP) channel to inhibition by MgATP; increases whole-cell K(ATP) current. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 132 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1581 The length of the canonical sequence.
Location on the sequence: help MAFMAAVTSVVYYHNIETSN F PKLLIALLVYWTLAFITKTI The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         MAFMAAVTSVVYYHNIETSNFPKLLIALLVYWTLAFITKTI

Rat                           MAFMAAITSVVYYHNIETSNFPKLLIALLIYWTLAFITKTI

Slime mold                    VVQWTVSLGLVY---LEMKKGQSRSWEIRLYWVFAFFVATV

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1581 ATP-binding cassette sub-family C member 8
Topological domain 123 – 134 Cytoplasmic
Alternative sequence 51 – 1581 Missing. In isoform 3.



Literature citations
A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.
Proks P.; Arnold A.L.; Bruining J.; Girard C.; Flanagan S.E.; Larkin B.; Colclough K.; Hattersley A.T.; Ashcroft F.M.; Ellard S.;
Hum. Mol. Genet. 15:1793-1800(2006)
Cited for: VARIANT PNDM3 LEU-132; CHARACTERIZATION OF VARIANT PNDM3 LEU-132; Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects.
Ellard S.; Flanagan S.E.; Girard C.A.; Patch A.M.; Harries L.W.; Parrish A.; Edghill E.L.; Mackay D.J.; Proks P.; Shimomura K.; Haberland H.; Carson D.J.; Shield J.P.; Hattersley A.T.; Ashcroft F.M.;
Am. J. Hum. Genet. 81:375-382(2007)
Cited for: VARIANTS PNDM3 LEU-45; SER-72; ALA-86; GLY-86; LEU-132; VAL-132; SER-207; LYS-208; GLU-209; LYS-211; PRO-225; ILE-229; ASP-263; LYS-382; GLU-1184; LYS-1326; ARG-1400 AND LEU-1522; CHARACTERIZATION OF VARIANTS PNDM3 LEU-132; SER-207; ILE-229; GLU-1184 AND LEU-1522;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.